SlideShare a Scribd company logo
1 of 34
DRUG DEVELOPMENT ,[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
STAGES OF DRUG APPROVAL by FDA
IND/NDA APPLICATION CONTENT ,[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
I. DRUG SUBSTANCE: (cont) ,[object Object],[object Object],[object Object]
[object Object],[object Object],I. DRUG SUBSTANCE: (cont)
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

More Related Content

What's hot

Comparison of stability testing requirements of ich with other
Comparison of stability testing requirements of ich with otherComparison of stability testing requirements of ich with other
Comparison of stability testing requirements of ich with otherJun Brown
 
Presentation on ICH guidelines Q5A (R1) and Q4B Annex 2 (R1)
Presentation on ICH guidelines Q5A (R1) and Q4B Annex 2 (R1)Presentation on ICH guidelines Q5A (R1) and Q4B Annex 2 (R1)
Presentation on ICH guidelines Q5A (R1) and Q4B Annex 2 (R1)HadiaNaz1
 
Stability testing of herbal natural products and its
Stability testing of herbal natural products and itsStability testing of herbal natural products and its
Stability testing of herbal natural products and itsSudhindraKini
 
Scale up process and post marketing survilence
Scale up process and post marketing survilenceScale up process and post marketing survilence
Scale up process and post marketing survilenceKAVITAAGRE
 
Impurities ICH Q3 Guidelines Au Vivek Jain
Impurities ICH Q3 Guidelines Au Vivek JainImpurities ICH Q3 Guidelines Au Vivek Jain
Impurities ICH Q3 Guidelines Au Vivek JainVivek Jain
 
ICH Q3B (R2):Impurities in new drug products
ICH Q3B (R2):Impurities in new drug products ICH Q3B (R2):Impurities in new drug products
ICH Q3B (R2):Impurities in new drug products Vinit Gohel
 
Bulk active post approval changes
Bulk active post approval changesBulk active post approval changes
Bulk active post approval changesbdvfgbdhg
 
Pharmaceutical development report (pdr)
Pharmaceutical development report (pdr)Pharmaceutical development report (pdr)
Pharmaceutical development report (pdr)Atul Bhombe
 
Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)Surendra Singh
 

What's hot (20)

Comparison of stability testing requirements of ich with other
Comparison of stability testing requirements of ich with otherComparison of stability testing requirements of ich with other
Comparison of stability testing requirements of ich with other
 
Process validation
Process validationProcess validation
Process validation
 
CGMP for IND phase I products
CGMP  for IND phase I productsCGMP  for IND phase I products
CGMP for IND phase I products
 
ICH Stability testing of new drug substances and products QA (R2) - 2015
ICH Stability testing of new drug substances and products QA (R2) - 2015ICH Stability testing of new drug substances and products QA (R2) - 2015
ICH Stability testing of new drug substances and products QA (R2) - 2015
 
Ich guidlines q and s
Ich guidlines  q and sIch guidlines  q and s
Ich guidlines q and s
 
Presentation on ICH guidelines Q5A (R1) and Q4B Annex 2 (R1)
Presentation on ICH guidelines Q5A (R1) and Q4B Annex 2 (R1)Presentation on ICH guidelines Q5A (R1) and Q4B Annex 2 (R1)
Presentation on ICH guidelines Q5A (R1) and Q4B Annex 2 (R1)
 
Ich guidelines
Ich guidelinesIch guidelines
Ich guidelines
 
ICH guidelines
ICH guidelinesICH guidelines
ICH guidelines
 
ICH guidelines
ICH guidelines ICH guidelines
ICH guidelines
 
Stability testing of herbal natural products and its
Stability testing of herbal natural products and itsStability testing of herbal natural products and its
Stability testing of herbal natural products and its
 
Scale up process and post marketing survilence
Scale up process and post marketing survilenceScale up process and post marketing survilence
Scale up process and post marketing survilence
 
ICH Q6A & ICH Q7
ICH Q6A & ICH Q7ICH Q6A & ICH Q7
ICH Q6A & ICH Q7
 
Impurities ICH Q3 Guidelines Au Vivek Jain
Impurities ICH Q3 Guidelines Au Vivek JainImpurities ICH Q3 Guidelines Au Vivek Jain
Impurities ICH Q3 Guidelines Au Vivek Jain
 
ICH Q3B (R2):Impurities in new drug products
ICH Q3B (R2):Impurities in new drug products ICH Q3B (R2):Impurities in new drug products
ICH Q3B (R2):Impurities in new drug products
 
Bulk active post approval changes
Bulk active post approval changesBulk active post approval changes
Bulk active post approval changes
 
ANDA Stability Requirements
ANDA Stability RequirementsANDA Stability Requirements
ANDA Stability Requirements
 
Ich q8 ppt
Ich q8 pptIch q8 ppt
Ich q8 ppt
 
Pharmaceutical development report (pdr)
Pharmaceutical development report (pdr)Pharmaceutical development report (pdr)
Pharmaceutical development report (pdr)
 
Supac
SupacSupac
Supac
 
Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)
 

Similar to CMC Logistics

Regulatory affairs cmc , post approval regulatory affairs
Regulatory affairs   cmc , post approval regulatory affairsRegulatory affairs   cmc , post approval regulatory affairs
Regulatory affairs cmc , post approval regulatory affairsArjunDhawale
 
NEW DRUG APPLICATION (NDA).pptx
NEW DRUG APPLICATION (NDA).pptxNEW DRUG APPLICATION (NDA).pptx
NEW DRUG APPLICATION (NDA).pptxAmitSahu546305
 
ICH guidelines on impurities in new drug products.pptx
ICH guidelines on impurities in new drug products.pptxICH guidelines on impurities in new drug products.pptx
ICH guidelines on impurities in new drug products.pptxDivya Pushp
 
CMC, post approval regulatory affairs, etc
CMC, post approval regulatory affairs, etcCMC, post approval regulatory affairs, etc
CMC, post approval regulatory affairs, etcJayeshRajput7
 
NEW DRUG APPLICATION ( NDA)
NEW DRUG APPLICATION ( NDA)NEW DRUG APPLICATION ( NDA)
NEW DRUG APPLICATION ( NDA)Suvarta Maru
 
Specification: Test procedure and acceptance criteria
Specification: Test procedure and acceptance criteriaSpecification: Test procedure and acceptance criteria
Specification: Test procedure and acceptance criteriaDigeshPatel17
 
Dr. Abhijath's RA Document (CMC, Post Approvals, Regulation of Combination Pr...
Dr. Abhijath's RA Document (CMC, Post Approvals, Regulation of Combination Pr...Dr. Abhijath's RA Document (CMC, Post Approvals, Regulation of Combination Pr...
Dr. Abhijath's RA Document (CMC, Post Approvals, Regulation of Combination Pr...Abhijath Murali
 
REGULATORY REQUIREMENTS IN ROW.pptx
REGULATORY REQUIREMENTS IN ROW.pptxREGULATORY REQUIREMENTS IN ROW.pptx
REGULATORY REQUIREMENTS IN ROW.pptxJeelJoshi8
 
NEW DRUG APPLICATION
NEW DRUG APPLICATIONNEW DRUG APPLICATION
NEW DRUG APPLICATIONSACHIN C P
 
GENERIC DRUG PRODUCT DEVELOPMENT.pptx
GENERIC DRUG PRODUCT DEVELOPMENT.pptxGENERIC DRUG PRODUCT DEVELOPMENT.pptx
GENERIC DRUG PRODUCT DEVELOPMENT.pptxKishor Singha
 
GMP Sub Part H, I & J
GMP Sub Part H, I & JGMP Sub Part H, I & J
GMP Sub Part H, I & JHARDIK PATEL
 
akshay regulatory seminar 1 productregistrationanddrugapprovalprocessinus.ppt
akshay regulatory seminar 1    productregistrationanddrugapprovalprocessinus.pptakshay regulatory seminar 1    productregistrationanddrugapprovalprocessinus.ppt
akshay regulatory seminar 1 productregistrationanddrugapprovalprocessinus.pptGaneshSureshKumbhar
 
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crastoABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crastoAnthony Melvin Crasto Ph.D
 

Similar to CMC Logistics (20)

Regulatory affairs cmc , post approval regulatory affairs
Regulatory affairs   cmc , post approval regulatory affairsRegulatory affairs   cmc , post approval regulatory affairs
Regulatory affairs cmc , post approval regulatory affairs
 
NEW DRUG APPLICATION (NDA).pptx
NEW DRUG APPLICATION (NDA).pptxNEW DRUG APPLICATION (NDA).pptx
NEW DRUG APPLICATION (NDA).pptx
 
ICH guidelines on impurities in new drug products.pptx
ICH guidelines on impurities in new drug products.pptxICH guidelines on impurities in new drug products.pptx
ICH guidelines on impurities in new drug products.pptx
 
CMC, post approval regulatory affairs, etc
CMC, post approval regulatory affairs, etcCMC, post approval regulatory affairs, etc
CMC, post approval regulatory affairs, etc
 
NEW DRUG APPLICATION ( NDA)
NEW DRUG APPLICATION ( NDA)NEW DRUG APPLICATION ( NDA)
NEW DRUG APPLICATION ( NDA)
 
Health Canada guidance for biotechnology products - Professor Peivand Pirouzi
Health Canada guidance for biotechnology products   - Professor Peivand Pirouzi Health Canada guidance for biotechnology products   - Professor Peivand Pirouzi
Health Canada guidance for biotechnology products - Professor Peivand Pirouzi
 
Specification: Test procedure and acceptance criteria
Specification: Test procedure and acceptance criteriaSpecification: Test procedure and acceptance criteria
Specification: Test procedure and acceptance criteria
 
Q5C.ppt
Q5C.pptQ5C.ppt
Q5C.ppt
 
Dr. Abhijath's RA Document (CMC, Post Approvals, Regulation of Combination Pr...
Dr. Abhijath's RA Document (CMC, Post Approvals, Regulation of Combination Pr...Dr. Abhijath's RA Document (CMC, Post Approvals, Regulation of Combination Pr...
Dr. Abhijath's RA Document (CMC, Post Approvals, Regulation of Combination Pr...
 
industrial prespectives of IND
industrial prespectives of INDindustrial prespectives of IND
industrial prespectives of IND
 
Q6 guidelines
Q6 guidelinesQ6 guidelines
Q6 guidelines
 
REGULATORY REQUIREMENTS IN ROW.pptx
REGULATORY REQUIREMENTS IN ROW.pptxREGULATORY REQUIREMENTS IN ROW.pptx
REGULATORY REQUIREMENTS IN ROW.pptx
 
NEW DRUG APPLICATION
NEW DRUG APPLICATIONNEW DRUG APPLICATION
NEW DRUG APPLICATION
 
GENERIC DRUG PRODUCT DEVELOPMENT.pptx
GENERIC DRUG PRODUCT DEVELOPMENT.pptxGENERIC DRUG PRODUCT DEVELOPMENT.pptx
GENERIC DRUG PRODUCT DEVELOPMENT.pptx
 
Q3 B R2 ICH Guideline
Q3 B R2 ICH GuidelineQ3 B R2 ICH Guideline
Q3 B R2 ICH Guideline
 
GMP Sub Part H, I & J
GMP Sub Part H, I & JGMP Sub Part H, I & J
GMP Sub Part H, I & J
 
Ich guidelines and protocols
Ich guidelines and protocolsIch guidelines and protocols
Ich guidelines and protocols
 
Q3 b r2_ step4
Q3 b r2_ step4Q3 b r2_ step4
Q3 b r2_ step4
 
akshay regulatory seminar 1 productregistrationanddrugapprovalprocessinus.ppt
akshay regulatory seminar 1    productregistrationanddrugapprovalprocessinus.pptakshay regulatory seminar 1    productregistrationanddrugapprovalprocessinus.ppt
akshay regulatory seminar 1 productregistrationanddrugapprovalprocessinus.ppt
 
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crastoABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
 

CMC Logistics

  • 1.
  • 2.
  • 3. STAGES OF DRUG APPROVAL by FDA
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.